BR112018013297A2 - composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo - Google Patents
composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmoInfo
- Publication number
- BR112018013297A2 BR112018013297A2 BR112018013297-7A BR112018013297A BR112018013297A2 BR 112018013297 A2 BR112018013297 A2 BR 112018013297A2 BR 112018013297 A BR112018013297 A BR 112018013297A BR 112018013297 A2 BR112018013297 A2 BR 112018013297A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- salt
- pyrazolone derivative
- substituted bicyclic
- preparing substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a uma composição farmacêutica compreendendo um derivado de azo pirazolona biciclo-substituído ou um sal do mesmo e um método de preparação do mesmo. em particular, a composição farmacêutica divulgada na presente invenção compreende o ácido (z)-5-(2-hidroxi-3-(2-(3-metil-5-oxo-1-(5,6,7,8-tetra-hidronaftalen-2-il)-1h-pirazol-4(5h)-ilideno)hidrazino)fenil)furano-2-carboxílico ou um sal farmaceuticamente aceitável do mesmo, e pelo menos um agente de enchimento opcionalmente selecionado de celulose, celulose microcristalina, lactose e amido. a composição tem uma boa estabilidade, taxa de dissolução e biodisponibilidade, e o processo de preparação é simples, econômico e rápido.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610046767.7 | 2016-01-22 | ||
CN201610046767 | 2016-01-22 | ||
PCT/CN2017/071219 WO2017124983A1 (zh) | 2016-01-22 | 2017-01-16 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013297A2 true BR112018013297A2 (pt) | 2018-12-11 |
Family
ID=59361374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013297-7A BR112018013297A2 (pt) | 2016-01-22 | 2017-01-16 | composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo |
Country Status (13)
Country | Link |
---|---|
US (1) | US11116752B2 (pt) |
EP (1) | EP3375442A4 (pt) |
JP (1) | JP6913684B2 (pt) |
KR (1) | KR20180103056A (pt) |
CN (2) | CN112220766B (pt) |
AU (1) | AU2017209224A1 (pt) |
BR (1) | BR112018013297A2 (pt) |
CA (1) | CA3008036A1 (pt) |
HK (1) | HK1243359A1 (pt) |
MX (1) | MX2018008342A (pt) |
RU (1) | RU2733844C2 (pt) |
TW (1) | TW201726129A (pt) |
WO (1) | WO2017124983A1 (pt) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ECSP077628A (es) * | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
CN101481352A (zh) | 2008-01-10 | 2009-07-15 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
CN101921232A (zh) * | 2009-06-11 | 2010-12-22 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用 |
CN102423485B (zh) * | 2011-12-08 | 2014-08-06 | 赵联华 | 含有醋酸去氨加压素的口服组合物及其制备方法 |
CN104844582A (zh) * | 2015-04-24 | 2015-08-19 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的二乙醇胺盐的结晶形式及其制备方法 |
-
2017
- 2017-01-16 CA CA3008036A patent/CA3008036A1/en not_active Abandoned
- 2017-01-16 RU RU2018127922A patent/RU2733844C2/ru active
- 2017-01-16 TW TW106101388A patent/TW201726129A/zh unknown
- 2017-01-16 MX MX2018008342A patent/MX2018008342A/es unknown
- 2017-01-16 KR KR1020187019560A patent/KR20180103056A/ko unknown
- 2017-01-16 JP JP2018532117A patent/JP6913684B2/ja active Active
- 2017-01-16 CN CN202011218917.0A patent/CN112220766B/zh active Active
- 2017-01-16 WO PCT/CN2017/071219 patent/WO2017124983A1/zh active Application Filing
- 2017-01-16 AU AU2017209224A patent/AU2017209224A1/en not_active Abandoned
- 2017-01-16 EP EP17741014.9A patent/EP3375442A4/en not_active Withdrawn
- 2017-01-16 BR BR112018013297-7A patent/BR112018013297A2/pt not_active Application Discontinuation
- 2017-01-16 US US16/070,388 patent/US11116752B2/en active Active
- 2017-01-16 CN CN201780000874.9A patent/CN107249585B/zh active Active
-
2018
- 2018-03-02 HK HK18103055.6A patent/HK1243359A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019506371A (ja) | 2019-03-07 |
RU2733844C2 (ru) | 2020-10-07 |
CN112220766B (zh) | 2023-08-11 |
CN107249585B (zh) | 2020-12-08 |
WO2017124983A1 (zh) | 2017-07-27 |
JP6913684B2 (ja) | 2021-08-04 |
US11116752B2 (en) | 2021-09-14 |
CN112220766A (zh) | 2021-01-15 |
HK1243359A1 (zh) | 2018-07-13 |
MX2018008342A (es) | 2019-01-31 |
CA3008036A1 (en) | 2017-07-27 |
CN107249585A (zh) | 2017-10-13 |
RU2018127922A3 (pt) | 2020-05-15 |
EP3375442A1 (en) | 2018-09-19 |
US20190022065A1 (en) | 2019-01-24 |
AU2017209224A1 (en) | 2018-07-26 |
EP3375442A4 (en) | 2018-12-26 |
RU2018127922A (ru) | 2020-02-25 |
KR20180103056A (ko) | 2018-09-18 |
TW201726129A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202012674PA (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
BR112018015369A2 (pt) | composição farmacêutica contendo inibidor de jak cinase ou sal farmaceuticamente aceitável do mesmo | |
MY196292A (en) | Steroid Derivative Fxr Agonist | |
MY182446A (en) | Region identifying operation for identfying region of a memory attribute unit corresponding to a target memory address | |
PH12016501043B1 (en) | Pharmaceutical compositions comprising dimethyl fumarate | |
BR112016007358A2 (pt) | bloco bruto para usinagem de próteses dentárias | |
MY183536A (en) | Pharmaceutical compositions comprising azd9291 | |
EA202091500A1 (ru) | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa | |
MX2017003943A (es) | Producto farmaceutico. | |
MX2018006903A (es) | Composicion farmaceutica. | |
MX2017017163A (es) | Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares. | |
TN2015000407A1 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
JP2019041808A5 (pt) | ||
PH12019502326A1 (en) | An isoxazole derivatives as nuclear receptor agonists and used thereof | |
PH12017501750A1 (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
JP2019041809A5 (pt) | ||
HRP20191434T1 (hr) | Liječenje eritromelalgije | |
BR112018013297A2 (pt) | composição farmacêutica compreendendo derivado de azo pirazolona biciclo-substituído ou sal do mesmo e método de preparação do mesmo | |
BR112019003281A2 (pt) | composição farmacêutica e métodos de usos | |
MX2017013788A (es) | Composicion farmaceutica estabilizada. | |
PH12018502446A1 (en) | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders | |
GEP20207127B (en) | 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |